Cargando…

The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer

The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, De-Wei, Lin, Po-Lin, Wang, Lee, Huang, Chi-Chou, Lee, Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399580/
https://www.ncbi.nlm.nih.gov/pubmed/28435452
http://dx.doi.org/10.7150/thno.18175
_version_ 1783230667912380416
author Wu, De-Wei
Lin, Po-Lin
Wang, Lee
Huang, Chi-Chou
Lee, Huei
author_facet Wu, De-Wei
Lin, Po-Lin
Wang, Lee
Huang, Chi-Chou
Lee, Huei
author_sort Wu, De-Wei
collection PubMed
description The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1α and YAP1 expression. Increased HIF-1α persistently promoted DDX3 expression via a KRAS/ROS/HIF-1α feedback loop. DDX3-mediated aggressiveness and CTX resistance were regulated by the YAP1/SIX2 axis in KRAS-WT cells and further confirmed in animal models. Kaplan-Meier and Cox regression analysis indicated that DDX3, KRAS, and YAP1 expression had prognostic value for OS and RFS in KRAS-WT and KRAS-mutated tumors, but SIX2 and YAP1/SIX2 were prognostic value only in KRAS-WT patients. The observation from patients seemed to support the mechanistic action of cell and animal models. We therefore suggest that combining YAP1 inhibitors with CTX may therefore suppress DDX3-mediated tumor aggressiveness and enhance CTX sensitivity in KRAS-WT colorectal cancer.
format Online
Article
Text
id pubmed-5399580
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53995802017-04-21 The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer Wu, De-Wei Lin, Po-Lin Wang, Lee Huang, Chi-Chou Lee, Huei Theranostics Research Paper The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1α and YAP1 expression. Increased HIF-1α persistently promoted DDX3 expression via a KRAS/ROS/HIF-1α feedback loop. DDX3-mediated aggressiveness and CTX resistance were regulated by the YAP1/SIX2 axis in KRAS-WT cells and further confirmed in animal models. Kaplan-Meier and Cox regression analysis indicated that DDX3, KRAS, and YAP1 expression had prognostic value for OS and RFS in KRAS-WT and KRAS-mutated tumors, but SIX2 and YAP1/SIX2 were prognostic value only in KRAS-WT patients. The observation from patients seemed to support the mechanistic action of cell and animal models. We therefore suggest that combining YAP1 inhibitors with CTX may therefore suppress DDX3-mediated tumor aggressiveness and enhance CTX sensitivity in KRAS-WT colorectal cancer. Ivyspring International Publisher 2017-02-27 /pmc/articles/PMC5399580/ /pubmed/28435452 http://dx.doi.org/10.7150/thno.18175 Text en ©Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wu, De-Wei
Lin, Po-Lin
Wang, Lee
Huang, Chi-Chou
Lee, Huei
The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title_full The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title_fullStr The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title_full_unstemmed The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title_short The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
title_sort yap1/six2 axis is required for ddx3-mediated tumor aggressiveness and cetuximab resistance in kras-wild-type colorectal cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399580/
https://www.ncbi.nlm.nih.gov/pubmed/28435452
http://dx.doi.org/10.7150/thno.18175
work_keys_str_mv AT wudewei theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT linpolin theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT wanglee theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT huangchichou theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT leehuei theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT wudewei yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT linpolin yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT wanglee yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT huangchichou yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer
AT leehuei yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer